Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 12, 2024
Discovery & Translation
Distillery spotlight: new mitochondrial mechanisms from academia
Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
BioCentury | Oct 12, 2023
Distillery Therapeutics
Targeting a mitochondrial STAT3 complex for lung cancer
BioCentury | Aug 8, 2023
Emerging Company Profile
Recludix: targeting STATs via their SH2 domains
San Diego company’s STAT6 program is partnered with Sanofi
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Feb 11, 2022
Distillery Therapeutics
Targeting endothelial YAP/TAZ to reduce tumor angiogenesis
BioCentury | Oct 23, 2021
Discovery & Translation
ESGCT preclinical roundup; plus Generation, Pionyr and more
BioCentury’s roundup of translational news
BioCentury | Aug 5, 2021
Deals
In down-to-the-wire decision, Vividion picks Bayer deal over IPO
Bayer obtains Vividion’s platform to reach difficult-to-drug targets, plus preclinical pipeline
BioCentury | Jun 24, 2021
Finance
Funding roundup: F-Prime leads series A for Toronto Dx company Adela; plus fresh funding for Strand, Tvardi, Orum, Glycomine and HutchMed
Meanwhile, digital biotech Pear readies for SPAC
BioCentury | May 3, 2021
Deals
With homegrown pipeline set to reach clinic, Roivant chooses Patient Square’s SPAC as vehicle to NASDAQ
A merger between Roivant and a SPAC sponsored by Patient Square will create a publicly traded umbrella company with $2.3 billion to put toward drug discovery, in-licensing and development, including
BioCentury | Mar 3, 2021
Product Development
With Kymera’s clinical debut, targeted protein degradation gets its first RCT
As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than
Items per page:
1 - 10 of 168